Ipsen Group

Ipsen is a global specialty-driven biopharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients.

Ipsen Group

Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases.  We also have a well-established and successful Consumer Healthcare business.  We are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.  

Ipsen group

Therapeutic areas

Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases.  We also have a well-established and successful Consumer Healthcare business. We are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.

Executive management

* members of the Executive Leadership Team

David Loew*

Chief Executive Officer

Bartosz (Bartek) Bednarz*

Executive Vice President,

Head of Global Product and Portfolio Strategy

Dominique Bery*

Executive Vice President, Strategy & Transformation

François Garnier*

Executive Vice President,

General Counsel

Benoît Hennion*

Executive Vice President,

CHC

Steven Hildemann*, M.D., PhD

Executive Vice President,

Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs

Dominique Laymand*

Executive Vice President,

Ethics and Social Responsibility Officer

Aymeric Le Chatelier*

Executive Vice-President,

Group Chief Financial Officer

Philippe Lopes-Fernandes*

Executive Vice President,

Chief Business Officer

Howard Mayer*, M.D.

Executive Vice President,

Head of Research and Development.

Régis Mulot*

Executive VP,

Chief Human Resources Officer

Aidan Murphy*

Executive Vice-President,

Technical Operations

Richard Paulson*

Chief Executive Officer,

At Ipsen North America

Patrice Zagame*

Executive Vice President,

Specialty Care International

Board Committees

The Board of Directors has set up six permanent committees and has defined both the composition and powers of these committees.

Ipsen history

Strategy

Financial outlook

The Group has updated its 2022 outlook taking into account the latest developments in its current business, mainly in the palovarotene development program:

  • Group net sales greater than €2.8 billion, assuming current level of exchange rates;
  • Core Operating margin greater than 28.0% of net sales

The outlook has been updated assuming no approval of additional meaningful products or indications (including no contribution from palovarotene), progressive entry of additional octreotide and lanreotide generics globally from 2021 and excluding the impact of incremental investments in pipeline expansion initiatives.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2020